Pharmacological therapy for acute stroke

Current Opinion in Investigational Drugs

Volumn 1, Issue 3, 2000, Pages 329-339

  Read, S J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Cerebral hemorrhage; Cerebral ischemia; Neuroprotection; Thrombolysis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; AMPA RECEPTOR ANTAGONIST; ANCROD; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CITICOLINE; CLOMETHIAZOLE; DARODIPINE; DEXTRORPHAN; DIZOCILPINE; FIBRINOLYTIC AGENT; FLUNARIZINE; HEPARIN; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; ISRADIPINE; MONOSIALOGANGLIOSIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; NIMODIPINE; OMEGA CONOTOXIN MVIIA; OPIATE ANTAGONIST; PROUROKINASE; RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR; SODIUM CHANNEL BLOCKING AGENT; STREPTOKINASE; TIRILAZAD; UNINDEXED DRUG;

BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; EXPERIMENTAL MODEL; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HUMAN; HYPOTENSION; MIDDLE CEREBRAL ARTERY OCCLUSION; MORTALITY; NEPHROTOXICITY; NEUROPROTECTION; NONHUMAN; RECANALIZATION; REVIEW; STROKE; THROMBOEMBOLISM; TREATMENT OUTCOME;

ACUTE DISEASE; ANIMALS; CEREBRAL HEMORRHAGE; CEREBROVASCULAR ACCIDENT; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; HUMANS; NEUROPROTECTIVE AGENTS; THROMBOLYTIC THERAPY;

EID: 0033708982     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (126)

1. Biology of ischemic cerebral cell death
2. Ischemic cell death in brain neurons
3. New magnetic resonance imaging methods for cerebrovascular disease: Emerging clinical applications
4. Calcium in ischemic cell death
5. Reducing calcium overload in the ischemic brain
6. Nitric oxide synthase in models of focal ischemia
7. Advances in the vascular pathophysiology of ischemic stroke
8. Apoptosis and cerebral ischemia
9. Tissue plasminogen activator for acute ischemic stroke
10. Randomized controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischemic stroke
11. Thrombolytic therapy with streptokinase in acute ischemic stroke
12. Streptokinase for acute ischemic stroke with relationship to time of administration
13. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke
14. Dichotomized efficacy end- points and global end-point analysis applied to the ECASS intention-to-treat data set: Post hoc analysis of ECASS I
15. Randomized double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators
16. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: A randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke
17. Intravenous tissue-type plasminogen activator for treatment of acute stroke: The Standard Treatment with Alteplase to Reverse Stroke (STARS) study
18. Use of tissue-type plasminogen activator for acute ischemic stroke: The Cleveland area experience
19. Treating acute stroke patients with intravenous tPA. The OSF stroke network experience
20. PROACT: A phase II randomized trial of recombinant prourokinase by direct arterial delivery in acute middle cerebral artery stroke
21. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: A randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism
22. Intravenous ancrod for treatment of acute ischemic stroke: The STAT study: A randomized controlled trial. Stroke Treatment with Ancrod Trial
23. The International Stroke Trial (IST): A randomized trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischemic stroke
24. Low-molecular-weight heparin for the treatment of acute ischemic stroke
25. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: A randomized controlled trial
26. Fraxiparine in Ischemic Stroke Study (FISS bis)
27. Low molecular-weight heparin versus aspirin in patients with acute ischemic stroke and atrial fibrillation: A double-blind randomized study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial
28. CAST: Randomized placebo-controlled trial of early aspirin use in 20,000 patients with acute ischemic stroke
29. Abciximab in acute ischemic stroke: A randomized, double-blind, placebo-controlled, dose-escalation study
30. A controlled trial of nimodipine in acute ischemic stroke
31. Double-blind study of nimodipine in non-severe stroke
32. Placebo-controlled trial of nimodipine in the treatment of acute ischemic cerebral infarction
33. Randomized, double-blind, placebo-controlled trial of nimodipine in acute stroke
34. Clinical trial of nimodipine in acute ischemic stroke
35. Nimodipine in acute ischemic stroke. Results of the Nimodipine German-Austrian Stroke Trial
36. Nimodipine in the treatment of acute MCA ischemic stroke
37. A randomized, double-blind, placebo-controlled trial of nimodipine in acute ischemic hemispheric stroke
38. Meta-analysis of oral nimodipine trials in acute ischemic stroke
39. The Canwin Study Group: Intravenous nimodipine in acute ischemic stroke
40. Intravenous Nimodipine West European Stroke Trial (INWEST) of nimodipine in the treatment of acute ischemic stroke
41. Effect of intravenous nimodipine on blood pressure and outcome after acute stroke
42. Isradipine in patients with acute ischemic cerebral infarction. An overview of the ASCLEPIOS programme
43. Flunarizine in acute ischemic stroke: A pilot study
44. Treatment of acute stroke with flunarizine IV
45. A double-blind, randomized trial of PY 108-068 in acute ischemic cerebral infarction
46. Safety, tolerability and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke
47. Safety and tolerance of oral dextromethorphan in patients at risk for brain ischemia
48. Tolerability of oral dextromethorphan in patients with a history of brain ischemia
49. Cerestat (CNS 1102), a non-competitive NMDA antagonist, in ischemic stroke patients: Dose-escalating safety study
50. Safety and tolerability study of aptiganel hydrochloride in patients with an acute ischemic stroke
51. Initial experience with remacemide hydrochloride in patients with acute ischemic stroke
52. A double-blind, randomized, placebo controlled, dose-escalation study of remacemide in patients with acute stroke
53. Remacemide hydrochloride: A double-blind, placebo-controlled, safety and tolerability study in patients with acute ischemic stroke
54. A randomized, double-blind, placebo-controlled pilot trial of intravenous magnesium sulfate in acute stroke
55. Dose optimization of intravenous magnesium sulfate after acute stroke
56. Randomized trial of CGS 19755, a glutamate antagonist, in acute ischemic stroke treatment
57. Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke. Results of a phase lla randomized trial
58. Termination of acute stroke studies involving selfotel treatment
59. Selfotel in acute ischemic stroke: Possible neurotoxic effects of an NMDA antagonist
60. Safety and tolerability of GV150526 (a glycine site antagonist at the N-methyl-D-aspartate receptor) in patients with acute stroke
61. Phase II studies of the glycine antagonist GV150526 in acute stroke: The North American experience
62. Dose escalation study of the NMDA glycine-site antagonist licostinel in acute ischemic stroke
63. Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: A randomized controlled trial. GAIN International Investigators
64. Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents. I. Evidence for efficacy in models of cerebral ischemia
65. Protective effects of ifenprodil on ischemic injury size, blood-brain barrier breakdown, and edema formation in focal cerebral ischemia
66. Effects of ifenprodil, a polyamine site NMDA receptor antagonist, on reperfusion injury after transient focal cerebral ischemia
67. The effect of eliprodil on the evolution of a focal cerebral ischemia in vivo
68. 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: A neuroprotectant for cerebral ischemia
69. The neuroprotective actions of 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) in a rat focal ischemia model
70. Cerebroprotective effect of a non-N-methyl-D-aspartate antagonist, GYKI 52466, after focal ischemia in the rat
71. Neuroprotective effect of the AMPA receptor antagonist LY-293558 in focal cerebral ischemia in the cat
72. YM872, a highly water-soluble AMPA receptor antagonist, preserves the homodynamic penumbra and reduces brain injury after permanent focal ischemia in rats
73. Neuroprotective efficacy of YM872, an α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, after permanent middle cerebral artery occlusion in rats
74. Neuroprotective effects of an AMPA receptor antagonist YM872 in a rat transient middle cerebral artery occlusion model
75. The neuroprotective effect of the novel AMPA receptor antagonist PD152247 (PNQX) in temporary focal ischemia in the rat
76. Delayed treatment with YM90K, an AMPA receptor antagonist, protects against ischemic damage after middle cerebral artery occlusion in rats
77. Neuroprotective actions of novel and potent ligands of group I and group II metabotropic glutamate receptors
78. Neuroprotection by metabotropic glutamate receptor glutamate receptor agonists: LY354740, LY379268 and LY389795
79. Pharmacokinetics of 619C89, a novel neuronal sodium channel inhibitor, in acute stroke patients after loading and discrete maintenance infusions
80. Safety and tolerability of 619C89 after acute stroke
81. Lubeluzole in acute ischemic stroke. A double-blind, placebo-controlled phase II trial
82. Lubeluzole treatment of acute ischemic stroke
83. Multinational randomized controlled trial of lubeluzole in acute ischemic stroke. European and Australian Lubeluzole Ischemic Stroke Study Group
84. Efficacy and tolerability of lifarizine in acute ischemic stroke
85. Safety study of tirilazad mesylate in patients with acute ischemic stroke (STIPAS)
86. Safety and efficacy of 6 mg/kg/day tirilazad mesylate in patients with acute ischemic stroke (TESS study)
87. A randomized trial of tirilazad mesylate in patients with acute stroke (RANTTAS)
88. High-dose tirilazad for acute stroke (RANTTAS II)
89. Tirilazad mesylate in acute ischemic stroke: A systematic review
90. Nitrone-based free radical traps as neuroprotective agents in cerebral ischemia and other pathologies
91. Neuroprotection by 2-h postischemia administration of two free radical scavengers, α-phenyl-n-tert-butyl-nitrone (PBN) and N-tert-butyl- (2-sulfophenyl)-nitrone (S-PBN), in rats subjected to focal embolic cerebral ischemia
92. Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat
93. High-dose intravenous naloxone for the treatment of acute ischemic stroke
94. A double blind randomized pilot trial of naloxone in the treatment of acute ischemic stroke
95. Cervene (Nalmefene) in acute ischemic stroke: Final results of a phase III efficacy study
96. Potential usefulness of basic fibroblast growth factor as a treatment for stroke
97. Anti-ICAM-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in the rat
98. Anti-intercellular adhesion molecule-1 antibody reduces ischemic cell damage after transient but not permanent middle cerebral artery occlusion in the Wistar rat
99. The Enlimomab acute stroke trial: Final results
100. Ganglioside GM1 in acute ischemic stroke. The SASS trial
101. Early treatment of stroke with monosialoganglioside GM-1. Efficacy and safety results of the early stroke trial
102. Clomethiazole acute stroke study (CLASS): Results of a randomized, controlled trial of clomethiazole versus placebo in 1360 acute stroke patients
103. Treatment of acute cerebral infarction with a choline precursor in a multicenter, double-blind, placebo-controlled study
104. A randomized dose-response trial of citicoline in acute ischemic stroke patients
105. A randomized efficacy trial of citicoline in patients with acute ischemic stroke
106. Piracetam and other structurally related nootropics
107. Treatment of acute ischemic stroke with piracetam
108. Ebselen in acute ischemic stroke: A placebo-controlled, double-blind clinical trial
109. Ebselen in acute middle cerebral artery occlusion: A placebo-controlled, double-blind clinical trial
110. Combined therapy with MK-801 and nimodipine for protection of ischemic brain damage
111. Combination therapy protects ischemic brain in rats. A glutamate antagonist plus a γ-aminobutyric acid agonist
112. Combination chemotherapy extends the therapeutic window to 60 minutes after stroke
113. Combined neuroprotection and reperfusion therapy for stroke. Effect of lubeluzole and diaspirin cross-linked hemoglobin in experimental focal ischemia
114. Synergistic neuroprotective effects by combining an NMDA or AMPA receptor antagonist with nitric oxide synthase inhibitors in global cerebral ischemia
115. Synergistic combinatorial stroke therapy: A quantal bioassay of a GABA agonist and a glutamate antagonist
116. Tissue plasminogen activator plus glutamate antagonist improves outcome after embolic stroke
117. Enhancing the efficacy of thrombolysis by AMPA receptor blockade with NBQX in a rat embolic stroke model
118. Neuroprotection by excitatory amino acid antagonist augments the benefit of thrombolysis in embolic stroke in rats
119. Neuroprotection with NBQX and thrombolysis with rt-PA in rat embolic stroke
120. Monoclonal antibodies preventing leukocyte activation reduce experimental neurologic injury and enhance efficacy of thrombolytic therapy
121. Neuroprotection afforded by a combination of eliprodil and a thrombolytic agent, rt-PA, in a rat thromboembolic stroke model
122. Evaluating the efficacy of citicoline in embolic ischemic stroke in rats: Neuroprotective effects when used alone or in combination with urokinase
123. Combination drug therapy and mild hypothermia: A promising treatment strategy for reversible, focal cerebral ischemia
124. Delayed treatment with AM-36, a novel neuroprotective agent, reduces neuronal damage after endothelin-1-induced middle cerebral artery occlusion in conscious rats
125. Results in 95 hemorrhagic stroke patients included in CLASS, a controlled trial of clomethiazole versus placebo in acute stroke patients
126. Expanding the window for thrombolytic therapy in acute stroke. The potential role of acute MRI for patient selection